/NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES/

WINNIPEG, Dec. 1, 2017 /CNW/ - DELTA 9 CANNABIS INC. (TSXV: NINE) ("Delta 9" or the "Company") is pleased to announce the appointment of Joanne Duhoux-Defehr to the board of directors of Delta 9.

Ms. Duhoux-Defehr is President of Triple D Developments Ltd., where she managed 1.5 million square feet of commercial and industrial buildings, including the building that houses Delta 9's production facility. Ms. Duhoux-Defehr earned a BA in Business Administration and a degree in Theology in the Netherlands, and a law degree from the University of San Francisco.

Ms. Duhoux-Defehr initially worked in the area of business litigation and intellectual property in the US as a member of the California bar. She currently sits on the board of several companies, and is a core founding member of the Delta 9 team. Ms. Duhoux-Defehr sat on the board of Delta 9 Bio-Tech Inc. (now a subsidiary of the Company) prior to its merger with SVT Capital Corp. (now the Company) in October this year, and now joins the board of Delta 9.

"We're very excited to officially welcome Joanne to the Delta 9 board, but in truth she has always been a key member of our team," said Delta 9 CEO John Arbuthnot. "Joanne was one of our early supporters, one of our first major investors, and has helped tremendously in the Company's growth through her deep knowledge of commercial real estate and legal issues."

Ms. Duhoux-Defehr, as President of Triple D Developments Ltd., was pivotal in negotiating and arranging for the development of the current Delta 9 production facility in Winnipeg, Mr. Arbuthnot added.

"Joanne's role in our Company's success thus far cannot be underestimated," said Mr. Arbuthnot. "But she remains equally important as Delta 9 moves into the next phase of our expansion."

Ms. Duhoux-Defehr says she is very pleased to join the board of Delta 9 given her long association with its founders, the father and son team of Delta 9 President Bill Arbuthnot and CEO John Arbuthnot.

"I am fascinated by disruptive industries, and there are few opportunities in anyone's life to take part in an entirely new industry that is being built from the ground up, so I feel very privileged to be part of the Delta 9 team," Ms. Duhoux-Defehr said. "But you don't just invest in an industry or a company; you invest in the people who operate that company. I have known Bill and John for many years now and I've been incredibly impressed with their work ethic, their innovative approach to this business, and their ability to make good use of capital."

Ms. Duhoux-Defehr is the fifth member of the board of directors of Delta 9. She joins fellow directors John Arbuthnot, Anthony Jackson, and Nitin Kaushal, and board Chair Bill Arbuthnot.

About Delta 9 Cannabis Inc.

Delta 9's wholly-owned subsidiary, Delta 9 Bio-Tech Inc., is a licensed producer of medical marijuana pursuant to the ACMPR and operates an 80,000 square foot production facility in Winnipeg, Manitoba, Canada. Delta 9's shares trade on the TSX Venture Exchange under the symbol "NINE".

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Disclaimer for Forward-Looking Information

Certain statements in this release are forward-looking statements, which reflect the expectations of management regarding the Company's future business plans and other matters. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Forward looking statements in this news release include statements relating to Delta 9's future expansion. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements, including that Delta 9's currently contemplated expansion and development plans may cease or otherwise change, Delta 9's production of cannabis may be lower than expected, Delta 9 may not obtain the required approvals from Health Canada, demand for Delta 9's products may be lower than anticipated, Delta 9's cost to produce its grow pods may be higher than expected and all other risk factors set forth in the filing statement of Delta 9 dated October 25, 2017 which has been filed on SEDAR. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are urged to consider these factors carefully in evaluating the forward-looking statements contained in this news release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by these cautionary statements. These forward-looking statements are made as of the date hereof and the Company disclaims any intent or obligation to update publicly any forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by applicable securities laws.

SOURCE Delta 9 Bio-Tech

For further information: Gary Symons, Director of Communications, [email protected], 250.300.9352